Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 6/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 5/20 | 0.39 |
| ▸ | FDPS | P14324 | 9/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL9443892 | 0.91 | GGPS1 (0.36) | GGPS1SMPD1FDPSCES2LPAR1 | |
| SCHEMBL28153086 | 0.84 | TP53 (0.34) | FDPS | |
| SCHEMBL2925757 | 0.84 | GGPS1 (0.39) | GGPS1SMPD1FDPSCES2LPAR1 | |
| SCHEMBL28946291 | 0.84 | GGPS1 (0.39) | GGPS1SMPD1FDPSCES2LPAR1 | |
| SCHEMBL24555294 | 0.82 | CA1 (0.36) | GGPS1SMPD1FDPSCA1CA2 | |
| SCHEMBL29166985 | 0.80 | CES2 (0.46) | CES2LPAR1LPAR3 | |
| Ammonia Solution, Strong SCHEMBL10892555 | 0.80 | GGPS1 (0.39) | GGPS1SMPD1FDPSCES2LPAR1 | |
| SCHEMBL29166828 | 0.80 | CES2 (0.46) | CES2LPAR1LPAR3 | |
| Ammonia Solution, Strong SCHEMBL2207612 | 0.80 | GGPS1 (0.39) | GGPS1SMPD1FDPSCES2LPAR1 | |
| SCHEMBL11601497 | 0.78 | GGPS1 (0.38) | GGPS1SMPD1FDPSCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11768156-B2 | Methods and compositions for assessing cell viability | Life Technologies Corporation (US) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11768156-B2 | Methods and compositions for assessing cell viability | BAX, CASP3, BAD | GGPS1 4337/4885SMPD1 271/4885FDPS 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.